Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$18.62 - $26.95 $8,230 - $11,911
-442 Reduced 3.54%
12,027 $225,000
Q4 2023

Feb 07, 2024

SELL
$17.1 - $22.26 $48,033 - $62,528
-2,809 Reduced 18.39%
12,469 $270,000
Q3 2023

Oct 31, 2023

BUY
$16.75 - $48.98 $11,691 - $34,188
698 Added 4.79%
15,278 $314,000
Q2 2023

Jul 19, 2023

SELL
$40.65 - $59.54 $77,804 - $113,959
-1,914 Reduced 11.6%
14,580 $686,000
Q1 2023

May 12, 2023

BUY
$37.27 - $46.57 $15,541 - $19,419
417 Added 2.59%
16,494 $692,000
Q4 2022

Feb 10, 2023

SELL
$32.2 - $43.61 $43,051 - $58,306
-1,337 Reduced 7.68%
16,077 $613,000
Q3 2022

Nov 03, 2022

BUY
$32.28 - $43.27 $288,324 - $386,487
8,932 Added 105.31%
17,414 $682,000
Q2 2022

Aug 09, 2022

SELL
$27.52 - $37.99 $67,286 - $92,885
-2,445 Reduced 22.38%
8,482 $274,000
Q1 2022

May 09, 2022

BUY
$30.71 - $45.71 $21,435 - $31,905
698 Added 6.82%
10,927 $362,000
Q4 2021

Feb 10, 2022

BUY
$37.06 - $47.11 $74,824 - $95,115
2,019 Added 24.59%
10,229 $435,000
Q3 2021

Nov 09, 2021

BUY
$40.26 - $57.37 $54,431 - $77,564
1,352 Added 19.71%
8,210 $364,000
Q2 2021

Aug 05, 2021

BUY
$54.88 - $79.29 $55,922 - $80,796
1,019 Added 17.45%
6,858 $390,000
Q1 2021

May 11, 2021

BUY
$70.65 - $96.76 $75,242 - $103,049
1,065 Added 22.31%
5,839 $437,000
Q4 2020

Feb 11, 2021

BUY
$58.41 - $89.06 $278,849 - $425,172
4,774 New
4,774 $413,000
Q4 2018

Mar 04, 2019

SELL
$81.94 - $139.71 $448,785 - $765,191
-5,477 Closed
0 $0
Q3 2018

Nov 09, 2018

SELL
$138.11 - $169.04 $526,199 - $644,042
-3,810 Reduced 41.03%
5,477 $774,000
Q2 2018

Aug 06, 2018

SELL
$140.36 - $175.76 $104,006 - $130,238
-741 Reduced 7.39%
9,287 $1.45 Million
Q1 2018

May 08, 2018

SELL
$152.15 - $192.33 $501,182 - $633,535
-3,294 Reduced 24.73%
10,028 $1.62 Million
Q4 2017

Feb 06, 2018

BUY
$60.72 - $167.34 $808,911 - $2.23 Million
13,322
13,322 $2.19 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $415M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.